NEW YORK (GenomeWeb) – Rheonix today said that it has raised $28.6 million in order to ramp up commercialization of its Encompass MDx and Encompass Optimum molecular diagnostic testing platforms. 

According to a document filed with the US Securities and Exchange Commission, the company is targeting $36.5 million for the financing round. Rheonix did not disclose the identities of the investors. 

Rand Capital and Cayuga Venture Fund co-lead the offering and was joined by existing investors Advantage Capital Partners and Gefinor Capital. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.